Jun 08, 2021 08:19 JST
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
In First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales
TOKYO and KENILWORTH, N.J., Jun 08, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A., and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Results from a new analysis evaluating health-related quality of life (HRQoL) based on patient-reported outcomes are being presented during an oral abstract session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). Data from CLEAR/KEYTNOTE-581 were originally presented at the 2021 Genitourinary Cancers Symposium (ASCO GU) and published in the New England Journal of Medicine, and data from this trial are currently under review with the U.S. Food and Drug Administration (FDA).
"This new analysis expands our understanding of the results we've seen from the CLEAR/KEYNOTE-581 trial in the treatment of patients with advanced renal cell carcinoma," said Dr. Robert Motzer, Medical Oncologist, Kidney Cancer Section Head, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center. "The additional data showed an improvement of specific health-related quality of life measures for patients who received LENVIMA plus KEYTRUDA compared with sunitinib, supporting the importance of this combination as a potential new first-line treatment option for patients."
"We continue to see an increasing number of patients diagnosed with advanced renal cell carcinoma and remain committed to improving outcomes for those facing this difficult-to-treat disease," said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck & Co., Inc., Kenilworth, N.J., U.S.A. Research Laboratories. "This new analysis builds on earlier findings from the CLEAR/KEYNOTE-581 trial and further supports the potential use of KEYTRUDA plus LENVIMA for the treatment of patients in the first-line setting."
"This analysis addresses questions of interest to healthcare professionals who treat patients with advanced renal cell carcinoma and reinforces the LENVIMA plus KEYTRUDA combination as a possible new treatment option for patients with this disease," said Dr. Takashi Owa, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai. "These results reflect Eisai and Merck's shared commitment to relentlessly pursue thorough scientific investigations with the goal of improving cancer care."
Data From Health-Related Quality-of-Life (HRQoL) Analysis From CLEAR/KEYNOTE-581
In an analysis of a secondary endpoint of HRQoL scores in the CLEAR/KEYNOTE-581 trial, LENVIMA plus KEYTRUDA and LENVIMA plus everolimus were evaluated to determine the impact on HRQoL compared to sunitinib in patients with advanced RCC. This was assessed based on patient-reported outcomes using three HRQoL and symptom measures: Functional Assessment of Cancer Therapy Kidney Symptom Index - Disease-Related Symptoms (FKSI-DRS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer - Core 30 (EORTC QLQ-C30) and European Quality of Life Five-Dimensions - 3-Level System (EuroQoL EQ-5D-3L). Unless otherwise noted, HRQoL analyses were based on data from randomized patients who received at least one dose of study treatment. No adjustments for multiple testing or estimation were used; p-values (two-sided) and confidence intervals (CI) are nominal and descriptive. Longitudinal change from baseline was assessed by mixed model analysis. Least squares mean differences (LSMD) and 95% CI were calculated from baseline. Time to deterioration (based on changes in HRQoL and disease-related symptom scores >/= meaningful thresholds) was assessed using time to first deterioration (TTD), which is the number of weeks between randomization and the first deterioration event, and time until definitive deterioration (TUDD), which is the number of weeks between randomization and the earliest deterioration event with no subsequent recovery above the deterioration threshold or no subsequent HRQoL assessment data. All times to deterioration were calculated and compared using the Kaplan-Meier method, stratified log-rank tests and Cox models.
LENVIMA plus KEYTRUDA demonstrated similar changes from baseline at mean follow-up (Week 46) on 14 out of 18 HRQoL and disease-related symptom scores and better HRQoL and disease-related symptom scores for the following measures ( LSMD [95% CI]): physical functioning (3.01 [0.48, 5.54]), fatigue (-2.80 [-5.52, -0.08]), dyspnea (-2.79 [-5.33, -0.25]) and constipation (-2.19 [-4.19, -0.18]), as measured by the QLQ-C30, versus sunitinib. LENVIMA plus everolimus demonstrated similar changes from baseline at mean follow-up (Week 46) on 14 out of 18 HRQoL and disease-related symptom scores and worse HRQoL and disease-related symptom scores in the following measures (LSMD [95% CI]): Global Health Score/QoL (-2.81[-5.08, -0.54]), pain (2.80 [0.11, 5.49]), appetite loss (4.23 [1.34, 7.13]) and diarrhea (5.26 [2.61, 7.91]) compared to sunitinib.
LENVIMA plus KEYTRUDA demonstrated a similar TTD in 14 out of 18 HRQoL and disease-related symptom scores, and a delay in TTD for physical functioning, dyspnea, appetite loss, and EQ-5D visual analog scale compared to sunitinib. LENVIMA plus KEYTRUDA demonstrated a delay in TUDD in 16 out of 18 HRQoL and disease-related symptom scores and a similar TUDD for cognitive functioning and financial difficulties compared to sunitinib.
For more information, visit https://www.eisai.com/news/2021/news202140.html.
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
Woven Capital Invests in Ridecell to Accelerate Global Growth in IoT-driven Automation for Mobility and Fleet Businesses
Jun 17, 2021 20:33 JST
Hitachi High-Tech Launches the Easy-to-Use AFM100 and AFM100 Plus Atomic Force Microscopes
Jun 17, 2021 17:33 JST
Mazda Announces New Technology and Product Policy towards 2030 Based on Sustainable Zoom-Zoom 2030
Jun 17, 2021 15:57 JST
Mitsubishi Corporation Participates in Laos Wind Farm Project
Jun 16, 2021 18:00 JST
Star Alliance, NEC and Sita Sign Teaming Agreement, Paving the Way to Expand Touchless Journeys Across Member Airlines
Jun 16, 2021 14:15 JST
Vodafone names NEC as a key partner for 5G massive MIMO radio units supporting commercial deployment of Open RAN in the UK
Jun 15, 2021 15:22 JST
Fujitsu to Initiate On-Site Vaccinations for Employees in Japan
Jun 15, 2021 11:59 JST
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
Jun 15, 2021 09:00 JST
JAXA and Honda to Begin a Feasibility Study on a Circulative Renewable Energy System
Jun 14, 2021 19:38 JST
One-Two in Race 100 for TOYOTA GAZOO Racing
Jun 14, 2021 12:20 JST
JCB Accelerates Business Expansion in ASEAN Region with Opening of New Department in Singapore
Jun 14, 2021 12:00 JST
All-New Lexus NX Premieres, Heraldling the Start of the Lexus Next Chapter
Jun 14, 2021 05:25 JST
Honda Announces the Establishment of Ashirase, Inc., a Startup Originated from IGNITION, a Honda New Business Creation Program
Jun 11, 2021 18:09 JST
Honda Begins Company-wide Expansion of its New Business Creation Program, "IGNITION," to Help Realize Ideas and Dreams of Honda Associates
Jun 11, 2021 17:10 JST
NEC upgrades its greenhouse gas reduction target to SBT1.5degC and joins RE100, a global renewable electricity initiative
Jun 11, 2021 11:02 JST
Northgate Public Services to improve patient experience and outcomes with acquisition of Vantage Health
Jun 11, 2021 10:24 JST
Drax and Mitsubishi Heavy Industries Sign Pioneering Deal Towards Delivery of the World's Largest Negative Emissions Project
Jun 10, 2021 17:12 JST
Showa Denko Contracts with Seagate to Jointly Develop HAMR Technology-based HD Media
Jun 10, 2021 15:00 JST
Honda and Komatsu Announce the Start of Joint Development of Micro Excavators Powered by Swappable Batteries
Jun 10, 2021 14:48 JST
Honda Launches All-New Civic Hatchback Teaser Page on its Company Website
Jun 10, 2021 12:33 JST